EYLEA HD Injection 8mg Two-Year Results From Pivotal PULSAR Trial In Wet Age-Related Macular Degeneration Presented At EURETINA
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals announced positive two-year results from the PULSAR trial investigating EYLEA HD Injection 8 mg in patients with wet age-related macular degeneration. The trial met its primary endpoint, with EYLEA HD patients achieving clinically equivalent vision gains to EYLEA at 48 weeks. EYLEA HD demonstrated durable vision gains at extended dosing intervals at the end of two years. EYLEA HD is being jointly developed by Regeneron and Bayer AG.
October 05, 2023 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Positive results from the PULSAR trial of EYLEA HD Injection could boost investor confidence in Regeneron Pharmaceuticals and potentially lead to increased demand for the company's stock.
The positive results from the PULSAR trial indicate that EYLEA HD Injection is effective in treating wet age-related macular degeneration. This could lead to increased demand for the product, which would boost Regeneron's revenues and potentially its stock price. The fact that EYLEA HD is being jointly developed with Bayer AG could also strengthen investor confidence in the company's ability to form strategic partnerships.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100